Shares of 10x Genomics rocketed to $35.40 on June 4, extending a blistering five-session rally of roughly 25% from $28.30 — a move fueled not by fresh headlines but by investors piling into a stock they believe has finally turned a corner after a brutal multi-year decline from its 2021 highs above $170. 10x Genomics Surges 25% in Five Days as Investors Chase a Turnaround Story — But Has the Stock Already Outrun the Fundamentals?
Shares of 10x Genomics vaulted 10.1% to $35.40 on June 4, capping a five-session sprint of roughly 25% from $28.30 — all without a single new company announcement. The rally, driven entirely by follow-through buying after upbeat first-quarter results and a technical breakout, now poses a critical question: is the stock pricing in a recovery that hasn't fully arrived?
• The Numbers Look Better, but Growth Is Still Modest
Q1 2026 revenue came in at $150.8 million with a net loss of $13.5 million; revenue fell 3% year-over-year but rose 9% excluding a $16.8 million one-time patent settlement from 2025.
Gross margin — the share of revenue left after production costs — improved to 70%, while operating expenses dropped 15%, narrowing losses significantly. That trajectory matters, but full-year guidance of $600–$625 million implies just 0%–4% growth stripping out last year's legal windfalls.
• The Stock Has Blown Past Where Wall Street Says It Should Be At $35.40, TXG now trades 49% above the consensus analyst price target. The Street's average target sits at just $21.22, with the highest call — $32, from Canaccord Genuity — already eclipsed.
Morgan Stanley, the most recent firm to weigh in, set a $22 target on May 12 expecting the stock to fall. This gap between market price and analyst expectations creates real risk of a snapback if momentum fades.
• A New Product Could Determine Whether the Rally Has Legs
10x Genomics expects to begin shipping its next-generation spatial biology platform — a tool that maps gene activity within tissue samples — in the second half of 2026, with early customer response described as "encouraging."
But management warned Q2 revenue will dip as customers delay purchases waiting for that product to ship. Successful adoption could reaccelerate growth; a soft launch would leave the stock dangerously exposed.
• A Healthy Cash Cushion Buys Time, but Insiders Are Selling
Cash and securities stood at $539.8 million at quarter-end, up $112.9 million year-over-year , giving the still-unprofitable company years of runway. Yet top executives recently "unloaded a wave of shares in a major insider sell-off." When management sells into strength, it warrants scrutiny — particularly when the stock is already trading well above every published price target on Wall Street.